Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption
Authors:
- 1 January 2017
- journal article
- research article
- Published by Sociedad Espanola de Patologia Digestiva (SEPD) in Revista Española de Enfermedades Digestivas
- Vol. 109 (10) , 684-689
Abstract
Pancreatic enzyme replacement therapy (PERT) remains a backbone in the nutritional treatment of cystic fibrosis. Currently, there is a lack of an evidence-based tool that allows dose adjustment. To date, no studies have found an association between PERT dose and fat absorption. Therefore, the aim of the study was to assess the influence of both the PERT dose and the variability in this dose on the coefficient of fat absorption (CFA). This is a retrospective longitudinal study of 16 pediatric patients (192 food records) with three consecutive visits to the hospital over a twelve-month period. Dietary fat intake and PERT were assessed via a four-day food record and fat content in stools was determined by means of a three-day stool sample collection. A beta regression model was built to explain the association between the CFA and the interaction between the PERT dose (lipase units [LU]/g dietary fat) and the variability in the PERT dose (standard deviation [SD]). The coefficient of fat absorption increased with the PERT dose when the variability in the dose was low. In contrast, even at the highest PERT dose values, the CFA decreased when the variability was high. The confidence interval suggested an association, although the analysis was not statistically significant. The variability in the PERT dose adjustment should be taken into consideration when performing studies on PERT efficiency. A clinical goal should be the maintenance of a constant PERT dose rather than trying to obtain an optimal value.Keywords
This publication has 19 references indexed in Scilit:
- Malabsorption blood test: Assessing fat absorption in patients with cystic fibrosis and pancreatic insufficiencyThe Journal of Clinical Pharmacology, 2015
- Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: A reconsiderationJournal of Cystic Fibrosis, 2013
- Delayed Small Bowel Transit in Children With Cystic Fibrosis and Pancreatic InsufficiencyJournal of Pediatric Gastroenterology and Nutrition, 2013
- Gastrointestinal Complications of Cystic FibrosisClinical Gastroenterology and Hepatology, 2013
- Comparison of Diagnostic Methods for Pancreatic Insufficiency in Infants With Cystic FibrosisJournal of Pediatric Gastroenterology and Nutrition, 2013
- Pancreatic enzyme replacement therapy in chronic pancreatitisBest Practice & Research Clinical Gastroenterology, 2010
- Cystic fibrosisThe Lancet, 2009
- An Enteric-Coated High-Buffered Pancrelipase Reduces Steatorrhea in Patients with Cystic Fibrosis: A Prospective, Randomized StudyJournal of the American Dietetic Association, 2006
- Diagnosis and Treatment of Intestinal Malabsorption in Cystic FibrosisPediatric Pulmonology, 2005
- Early Diagnosis of Cystic Fibrosis Through Neonatal Screening Prevents Severe Malnutrition and Improves Long-Term GrowthPediatrics, 2001